Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Biofactory introduces kits for assessment of protein-DNA interactions, targeting researchers and industry

15.11.2012
The Biofactory introduced today its ColoQuik line of label-free kits for the rapid colorimetric detection of protein-DNA interactions in biomedical research labs and the pharmaceutical industry. The kits are based on a unique technology developed by A*STAR Singapore.

Based on a unique technology developed by A*STAR Singapore, these inventive and easy-to-use kits are versatile, effective and quick in the screening for modulators of protein-DNA interactions, as well as quality control (QC) analysis of transcription factor production.

The Biofactory, a leading innovator in incubating biomedical and life sciences related technologies, introduced today its ColoQuik™ line of label-free kits for the rapid colorimetric detection of protein-DNA interactions in biomedical research labs and the pharmaceutical industry. These kits are based on technology licensed from the Institute of Materials Research and Engineering (IMRE), a research institute of the Agency for Science, Technology and Research (A*STAR), Singapore’s lead government agency for fostering world-class scientific research. The Biofactory has three kits in its pipeline, each customized for the assessment of a well-known transcription factor in cancer: ERá, ERâ, and p53.

The ColoQuik™ kits will be particularly suited for pharmaceutical companies or academic researchers who require tools for the analysis of protein-DNA interactions at a higher level of throughput. ColoQuik™ kits will find strong utility in primary screens for drugs that can modulate protein-DNA interactions, or in QC analyses of purified DNA-binding proteins based on their DNA-binding capacities.

Conventional techniques for the analysis of protein-DNA interactions tend to pose numerous restrictions and drawbacks upon their users in terms of assay time, expense and throughput. Some methods can involve extensive protocol optimization and materials preparation, with tedious procedures lasting as long as 2 days. Others necessitate tagging of the DNA with radioactive isotopes prior to running the test, which can result in safety and environmental issues. Label-free assays for academia or industry have typically involved hardware and software costs, which limit their utility for primary drug screening.

In comparison, users will find ColoQuik™ assays much easier to use. These tests require only a half-hour to complete on average, and allow for instant visual detection of reagent colour changes based on the quality and affinity of binding between a protein and a specified DNA sequence. The test does not require radioactive or fluorescent labeling of DNA which leads to significant time and cost savings on preparatory work. ColoQuik™ tests require only standard equipment such as microplate absorbance readers for semi-quantitative readouts. As such, these kits are amenable to high-throughput drug discovery applications and batch functional analysis of transcription factor production.

The key technology in the kits is the custom-made, nanometer-sized metal particles created at A*STAR’s IMRE. The particles act as probes which give off different colours depending on the specific protein-DNA combinations that are formed in the nanoparticle solution. “These kits offer the easiest and fastest ways to date for scientists to analyse a particular DNA binding protein for its impact on the gene transcription mechanism of specific diseases,” said Dr Su Xiaodi, the IMRE Senior Scientist who led the nanoparticle work.

The Biofactory has received beneficial technology assessments from leading scientists who have utilized the technology for their specific experiments. The Biofactory is in the process of manufacturing and marketing the kits to research institutions and pharmaceutical laboratories both in Singapore and around the world.

“The licensing of our materials technology for use in protein-DNA analysis is testament to the value of our research to industry. This development is also a prime example of cross-disciplinary research in action,” said Prof Andy Hor, IMRE’s Executive Director. “We look forward to seeing this revolutionary new technique being developed further to aid in advancing global healthcare.”
“The Biofactory is honoured to be part of the commercialization process. With our expertise in product and business development, we will continue to guide other Singapore-based biomedical innovations towards market success,” said Theodore Tan, Managing Director of The Biofactory.

The ColoQuik™ kits will be introduced at this year’s MEDICA exhibition in Dusseldorf, Germany. For more product information or licensing enquiries, interested parties may visit http://thebiofactory.com/coloquik.

Media enquiries should be directed to:

Theodore Tan
The Biofactory Pte Ltd
Email: theotan@biofactory.com
Mobile: (65) 9-638-4201

Eugene Low
A*STAR IMRE (Corporate Communications)
Email: loweom@scei.a-star.edu.sg
Mobile: (65) 9-230-9235
About The Biofactory Pte Ltd
The Biofactory is a biomedical incubator that catalyses the commercialisation of innovative technologies. With qualified professionals in a wide number of areas, the Biofactory has the technical expertise and experience to bring technologies to market at an accelerated pace. www.thebiofactory.com
About A*STAR’s Institute of Materials Research and Engineering (IMRE)
The Institute of Materials Research and Engineering (IMRE) is a research institute of the Agency for Science, Technology and Research (A*STAR). The Institute has capabilities in materials analysis & characterization, design & growth, patterning & fabrication, as well as synthesis & integration. We house a range of state-of-the-art equipment for materials research including development, processing and characterization. IMRE conducts a wide range of research, which includes novel materials for sensors & transducers, consumer care, organic solar cells, photovoltaics, printed electronics, catalysis, bio-mimetics, microfluidics, quantum dots, heterostructures, sustainable materials and atom technology, among others. We collaborate actively with other research institutes, universities, public bodies, and a wide spectrum of industrial companies, both globally and locally. For more information about IMRE, please visit www.imre.a-star.edu.sg

About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector agency that fosters world-class scientific research and talent to drive economic growth and transform Singapore into a vibrant knowledge-based and innovation driven economy. In line with its mission-oriented mandate, A*STAR spearheads research and development in fields that are essential to growing Singapore’s manufacturing sector and catalysing new growth industries. A*STAR supports these economic clusters by providing intellectual, human and industrial capital to its partners in industry. A*STAR oversees 20 biomedical sciences and physical sciences and engineering research entities, located in the Biopolis and Fusionopolis as well as their vicinity. These two R&D hubs house a bustling and diverse community of local and international research scientists and engineers from A*STAR’s research entities as well as a growing number of corporate laboratories. Please visit www.a-star.edu.sg for more information.

Eugene Low | Research asia research news
Further information:
http://www.a-star.edu.sg
http://www.researchsea.com

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Osaka university researchers make the slipperiest surfaces adhesive

18.10.2017 | Materials Sciences

Space radiation won't stop NASA's human exploration

18.10.2017 | Physics and Astronomy

Los Alamos researchers and supercomputers help interpret the latest LIGO findings

18.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>